These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

525 related items for PubMed ID: 18371481

  • 1. Effects of pioglitazone on major adverse cardiovascular events in high-risk patients with type 2 diabetes: results from PROspective pioglitAzone Clinical Trial In macro Vascular Events (PROactive 10).
    Wilcox R, Kupfer S, Erdmann E, PROactive Study investigators.
    Am Heart J; 2008 Apr; 155(4):712-7. PubMed ID: 18371481
    [Abstract] [Full Text] [Related]

  • 2. CHICAGO, PERISCOPE and PROactive: CV risk modification in diabetes with pioglitazone.
    Betteridge DJ.
    Fundam Clin Pharmacol; 2009 Dec; 23(6):675-9. PubMed ID: 19744248
    [Abstract] [Full Text] [Related]

  • 3. Cardiovascular risk and cardiometabolic protection: role of glitazones.
    Petrazzi L, Grassi D, Polidoro L, D'Aurelio A, Croce G, Properzi G, Tiberti S, Desideri G, Ferri C.
    J Nephrol; 2008 Dec; 21(6):826-35. PubMed ID: 19034866
    [Abstract] [Full Text] [Related]

  • 4. The effect of pioglitazone on recurrent myocardial infarction in 2,445 patients with type 2 diabetes and previous myocardial infarction: results from the PROactive (PROactive 05) Study.
    Erdmann E, Dormandy JA, Charbonnel B, Massi-Benedetti M, Moules IK, Skene AM, PROactive Investigators.
    J Am Coll Cardiol; 2007 May 01; 49(17):1772-80. PubMed ID: 17466227
    [Abstract] [Full Text] [Related]

  • 5. Thiazolidinediones in type 2 diabetes: a cardiology perspective.
    Khanderia U, Pop-Busui R, Eagle KA.
    Ann Pharmacother; 2008 Oct 01; 42(10):1466-74. PubMed ID: 18698014
    [Abstract] [Full Text] [Related]

  • 6. [Effects of thiazolidinediones on dyslipidemia in patients with type 2 diabetes. Are all equally vasoprotective?].
    Haberbosch W.
    Herz; 2007 Feb 01; 32(1):51-7. PubMed ID: 17323035
    [Abstract] [Full Text] [Related]

  • 7. Diabetes patients requiring glucose-lowering therapy and nondiabetics with a prior myocardial infarction carry the same cardiovascular risk: a population study of 3.3 million people.
    Schramm TK, Gislason GH, Køber L, Rasmussen S, Rasmussen JN, Abildstrøm SZ, Hansen ML, Folke F, Buch P, Madsen M, Vaag A, Torp-Pedersen C.
    Circulation; 2008 Apr 15; 117(15):1945-54. PubMed ID: 18378618
    [Abstract] [Full Text] [Related]

  • 8. Efficacy and safety of atorvastatin in the prevention of cardiovascular end points in subjects with type 2 diabetes: the Atorvastatin Study for Prevention of Coronary Heart Disease Endpoints in non-insulin-dependent diabetes mellitus (ASPEN).
    Knopp RH, d'Emden M, Smilde JG, Pocock SJ.
    Diabetes Care; 2006 Jul 15; 29(7):1478-85. PubMed ID: 16801565
    [Abstract] [Full Text] [Related]

  • 9. PROactive: time for a critical appraisal.
    Betteridge DJ, DeFronzo RA, Chilton RJ.
    Eur Heart J; 2008 Apr 15; 29(8):969-83. PubMed ID: 18375395
    [Abstract] [Full Text] [Related]

  • 10. Effects of pioglitazone in patients with type 2 diabetes with or without previous stroke: results from PROactive (PROspective pioglitAzone Clinical Trial In macroVascular Events 04).
    Wilcox R, Bousser MG, Betteridge DJ, Schernthaner G, Pirags V, Kupfer S, Dormandy J, PROactive Investigators.
    Stroke; 2007 Mar 15; 38(3):865-73. PubMed ID: 17290029
    [Abstract] [Full Text] [Related]

  • 11. Effect of sibutramine on cardiovascular outcomes in overweight and obese subjects.
    James WP, Caterson ID, Coutinho W, Finer N, Van Gaal LF, Maggioni AP, Torp-Pedersen C, Sharma AM, Shepherd GM, Rode RA, Renz CL, SCOUT Investigators.
    N Engl J Med; 2010 Sep 02; 363(10):905-17. PubMed ID: 20818901
    [Abstract] [Full Text] [Related]

  • 12. The thiazolidinediones rosiglitazone and pioglitazone and the risk of coronary heart disease: a retrospective cohort study using a US health insurance database.
    Ziyadeh N, McAfee AT, Koro C, Landon J, Arnold Chan K.
    Clin Ther; 2009 Nov 02; 31(11):2665-77. PubMed ID: 20110009
    [Abstract] [Full Text] [Related]

  • 13. Greater clinical benefit of more intensive oral antiplatelet therapy with prasugrel in patients with diabetes mellitus in the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-Thrombolysis in Myocardial Infarction 38.
    Wiviott SD, Braunwald E, Angiolillo DJ, Meisel S, Dalby AJ, Verheugt FW, Goodman SG, Corbalan R, Purdy DA, Murphy SA, McCabe CH, Antman EM, TRITON-TIMI 38 Investigators.
    Circulation; 2008 Oct 14; 118(16):1626-36. PubMed ID: 18757948
    [Abstract] [Full Text] [Related]

  • 14. Long-term lipid effects of pioglitazone by baseline anti-hyperglycemia medication therapy and statin use from the PROactive experience (PROactive 14).
    Spanheimer R, Betteridge DJ, Tan MH, Ferrannini E, Charbonnel B, PROactive Investigators.
    Am J Cardiol; 2009 Jul 15; 104(2):234-9. PubMed ID: 19576353
    [Abstract] [Full Text] [Related]

  • 15. Thiazolidinediones: effects on the development and progression of type 2 diabetes and associated vascular complications.
    Krentz A.
    Diabetes Metab Res Rev; 2009 Feb 15; 25(2):112-26. PubMed ID: 19219860
    [Abstract] [Full Text] [Related]

  • 16. Association of LDL cholesterol and inflammation with cardiovascular events and mortality in hemodialysis patients with type 2 diabetes mellitus.
    Krane V, Winkler K, Drechsler C, Lilienthal J, März W, Wanner C, German Diabetes and Dialysis Study Investigators.
    Am J Kidney Dis; 2009 Nov 15; 54(5):902-11. PubMed ID: 19781835
    [Abstract] [Full Text] [Related]

  • 17. Incidence of cardiovascular events in which 2 thiazolidinediones are used as add-on treatments for type 2 diabetes mellitus in a Taiwanese population.
    Wang CC, Chen WL, Kao TW, Chang YW, Loh CH, Chou CC.
    Clin Ther; 2011 Dec 15; 33(12):1904-13. PubMed ID: 22118894
    [Abstract] [Full Text] [Related]

  • 18. Effect of a multifactorial intervention on mortality in type 2 diabetes.
    Gaede P, Lund-Andersen H, Parving HH, Pedersen O.
    N Engl J Med; 2008 Feb 07; 358(6):580-91. PubMed ID: 18256393
    [Abstract] [Full Text] [Related]

  • 19. Pioglitazone and the risk of myocardial infarction and other major adverse cardiac events: a meta-analysis of randomized, controlled trials.
    Nagajothi N, Adigopula S, Balamuthusamy S, Velazquez-Cecena JL, Raghunathan K, Khraisat A, Singh S, Molnar J, Khosla S, Benatar D.
    Am J Ther; 2008 Feb 07; 15(6):506-11. PubMed ID: 19127132
    [Abstract] [Full Text] [Related]

  • 20. Pioglitazone and cardiovascular risk. A comprehensive meta-analysis of randomized clinical trials.
    Mannucci E, Monami M, Lamanna C, Gensini GF, Marchionni N.
    Diabetes Obes Metab; 2008 Dec 07; 10(12):1221-38. PubMed ID: 18505403
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 27.